10x Genomics, Inc.
TXG
$27.48
$1.194.53%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 19.81% | 17.33% | 14.15% | 7.42% | 5.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.81% | 17.33% | 14.15% | 7.42% | 5.28% |
| Cost of Revenue | 74.39% | 84.27% | 65.57% | 92.46% | 102.20% |
| Gross Profit | 3.28% | 1.47% | 2.72% | -5.95% | -8.07% |
| SG&A Expenses | 14.54% | 15.31% | 16.77% | 16.86% | 14.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.04% | 19.85% | 19.82% | 24.80% | 28.65% |
| Operating Income | -20.76% | -28.54% | -42.98% | -148.84% | -328.50% |
| Income Before Tax | -53.58% | -35.30% | -20.77% | -101.60% | -201.54% |
| Income Tax Expenses | 57.26% | -15.75% | 25.39% | -8.12% | -10.63% |
| Earnings from Continuing Operations | -53.67% | -33.56% | -20.91% | -95.69% | -185.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.67% | -33.56% | -20.91% | -95.69% | -185.11% |
| EBIT | -20.76% | -28.54% | -42.98% | -148.84% | -328.50% |
| EBITDA | -17.23% | -27.99% | -48.57% | -213.18% | -709.45% |
| EPS Basic | -49.05% | -29.72% | -18.08% | -91.47% | -177.24% |
| Normalized Basic EPS | -10.54% | -13.58% | -27.42% | -127.92% | -285.18% |
| EPS Diluted | -49.05% | -29.72% | -18.08% | -91.47% | -177.24% |
| Normalized Diluted EPS | -10.54% | -13.58% | -27.42% | -127.92% | -285.18% |
| Average Basic Shares Outstanding | 2.90% | 2.71% | 2.65% | 2.80% | 3.19% |
| Average Diluted Shares Outstanding | 2.90% | 2.71% | 2.65% | 2.80% | 3.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
